Skip to main content
BGI Genomics Co., Ltd. logo

BGI Genomics Co., Ltd. — Investor Relations & Filings

Ticker · 300676 ISIN · CNE100003449 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 1,656 across all filing types
Latest filing 2019-08-27 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300676

About BGI Genomics Co., Ltd.

https://www.bgi.com

BGI Genomics Co., Ltd. is a leading provider of integrated solutions for precision medicine, specializing in genomic sequencing and proteomic services. The company offers a comprehensive portfolio of clinical diagnostics and research services across various fields, including reproductive health, oncology, and infectious diseases. Key products include non-invasive prenatal testing, hereditary cancer screening, and pathogen identification tools. Leveraging proprietary DNBseq sequencing technology, BGI Genomics provides high-throughput, cost-effective genomic data analysis to healthcare providers, research institutions, and pharmaceutical companies worldwide. The organization focuses on advancing personalized medicine through large-scale genomic research and the development of innovative diagnostic applications, aiming to improve health outcomes by making advanced genetic insights accessible to a global population.

Recent filings

Filing Released Lang Actions
关于增加2019年度预计日常关联交易额度的公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement from Shenzhen BGI Genomics Co., Ltd. regarding the increase in the 2019 estimated daily related-party transaction quota. It includes extensive information about related parties, transaction categories, amounts, pricing policies, and the necessity of these transactions. The content focuses on operational and financial details of related-party transactions, which are typical disclosures required by stock exchanges for transparency and compliance. There is no indication that this is a full annual or interim financial report, audit report, or earnings release. It is not a call transcript, management change, or merger announcement. The document is regulatory in nature, providing a compliance disclosure about related-party transactions as per Shenzhen Stock Exchange rules. Given the detailed nature and regulatory compliance focus, this fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2019-08-27 Chinese
2019年半年度募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "2019 Semi-Annual Special Report on the Deposit and Actual Use of Raised Funds" by Shenzhen BGI Genomics Co., Ltd. It details the use and management of funds raised through a public offering of A shares, including amounts raised, usage, bank accounts, and compliance with regulatory guidelines. The content focuses on the specific use of capital raised, investment projects, and compliance with securities regulations. It is a specialized report on the use of fundraising proceeds rather than a general financial report or earnings release. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document length is over 7000 characters and contains detailed financial data related to fundraising usage, not just an announcement or certification, so it is not RPA or RNS. Therefore, the correct classification is CAP with high confidence.
2019-08-27 Chinese
独立董事关于第二届董事会第十一次会议相关事项的事前认可意见
Board/Management Information Classification · 95% confidence The document is a formal opinion from independent directors regarding matters to be discussed at the company's 11th board meeting of the second session. It references compliance with regulatory guidelines from the China Securities Regulatory Commission and Shenzhen Stock Exchange rules, and discusses approval of related party transactions and investment fund participation. The document is a pre-approval or endorsement statement by independent directors rather than a full report or announcement of financial results. It does not contain financial statements or earnings data, nor is it a notice of voting results or a proxy solicitation. It is also not a regulatory filing or certification letter. The content aligns with Board/Management Information (MANG) as it relates to board meeting matters and approvals by directors.
2019-08-27 Chinese
独立董事关于第二届董事会第十一次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is titled as an independent opinion from independent directors regarding matters discussed at the 11th meeting of the second board of directors of Shenzhen BGI Genomics Co., Ltd. It discusses various corporate governance and financial matters such as the use of raised funds, related party transactions, asset impairment, accounting policy changes, bank credit lines, guarantees, and investment fund participation. The document references compliance with stock exchange rules and company articles, and provides independent directors' opinions on these matters. It is not a full financial report, earnings release, or audit report, but rather a formal opinion related to board meeting agenda items. The document length is about 2993 characters, which is relatively short and focused on governance and board meeting related opinions. This fits best with the category of Board/Management Information (MANG), which covers announcements of changes or opinions from the board or senior management related to company governance and decisions. It is not a report publication announcement or regulatory filing as it contains substantive independent opinions rather than just a notice. Therefore, the classification is MANG with high confidence.
2019-08-27 Chinese
中信证券股份有限公司关于公司2019年半年度跟踪报告
Interim / Quarterly Report Classification · 95% confidence The document is a detailed 2019 semi-annual tracking report by CITIC Securities on Shenzhen BGI Genomics Co., Ltd. It includes extensive information on the sponsor's work overview, company governance, internal controls, compliance with regulatory decisions, shareholder commitments, shareholding lock-up and reduction commitments, share repurchase and price stabilization commitments, dividend policies, and other corporate governance and compliance matters. The document is comprehensive and contains substantive financial and operational information for a half-year period (2019 H1). It is not a brief announcement or a certification letter but a full report with detailed analysis and findings. Therefore, it fits the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year containing actual financial statements or substantive financial data and analysis. H1 2019
2019-08-27 Chinese
关于召开2019年第四次临时股东大会的通知公告
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a detailed notice about the convening of the 2019 fourth extraordinary general meeting (临时股东大会) of Shenzhen BGI Genomics Co., Ltd. It includes information about the meeting date, time, location, agenda items, voting procedures (including online voting), registration details, and attachments such as proxy forms and shareholder registration forms. The content is focused on informing shareholders about the meeting logistics and agenda, not on presenting financial results or management commentary. There is no financial data, earnings information, or report publication mentioned. This type of document is a formal announcement to shareholders about a shareholders' meeting, which fits the category of Proxy Solicitation & Information Statement (PSI), as it provides materials to shareholders to inform and solicit votes for the meeting.
2019-08-27 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.